Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Related Citations for PubMed (Select 21489817)

1.

Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial.

Finlen Copeland CA, Davis WA, Snyder LD, Banks M, Avery R, Davis RD, Palmer SM.

J Heart Lung Transplant. 2011 Sep;30(9):990-6. doi: 10.1016/j.healun.2011.02.017. Epub 2011 Apr 13.

PMID:
21489817
2.

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.

Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Valentine V, McCall J, Chow SC, Davis RD, Avery R.

Ann Intern Med. 2010 Jun 15;152(12):761-9. doi: 10.7326/0003-4819-152-12-201006150-00003.

PMID:
20547904
3.

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.

Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group.

Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.

PMID:
22094954
4.

A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.

Monforte V, Lopez C, Santos F, Zurbano F, de la Torre M, Sole A, Gavalda J, Ussetti P, Lama R, Cifrian J, Borro JM, Pastor A, Len O, Bravo C, Roman A.

Am J Transplant. 2009 May;9(5):1134-41. doi: 10.1111/j.1600-6143.2009.02574.x. Epub 2009 Mar 16.

5.

Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.

Jaksch P, Zweytick B, Kerschner H, Hoda AM, Keplinger M, Lang G, Aigner C, Klepetko W.

J Heart Lung Transplant. 2009 Jul;28(7):670-5. doi: 10.1016/j.healun.2009.03.012. Epub 2009 May 13.

PMID:
19560694
6.

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.

Pharmacotherapy. 2004 Oct;24(10):1323-30.

PMID:
15628830
7.

Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.

Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.

Chest. 1999 Nov;116(5):1265-72.

PMID:
10559085
8.

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.

Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.

Transpl Infect Dis. 2012 Jun;14(3):248-58. doi: 10.1111/j.1399-3062.2012.00723.x. Epub 2012 Mar 5.

PMID:
22385394
9.

A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.

Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, Jackson K, Nia S, Lien D.

Am J Transplant. 2005 Jun;5(6):1462-8.

10.

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.

Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.

J Heart Lung Transplant. 2010 Sep;29(9):1014-20. doi: 10.1016/j.healun.2010.04.022. Epub 2010 Jul 3.

PMID:
20598582
11.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3182-6.

PMID:
16213344
12.

Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.

Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S, Palau J, Romero M, Montava A, Senent L, Martínez J, Jarque I, Salavert M, Córdoba J, Gómez L, Weiss S, Moscardó F, de la Rubia J, Larrea L, Sanz MA, Sanz GF.

Biol Blood Marrow Transplant. 2009 Jun;15(6):730-40. doi: 10.1016/j.bbmt.2009.03.002. Epub 2009 Apr 11.

PMID:
19450758
13.

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.

Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group.

Am J Transplant. 2004 Apr;4(4):611-20.

14.

Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.

Kalil AC, Freifeld AG, Lyden ER, Stoner JA.

PLoS One. 2009;4(5):e5512. doi: 10.1371/journal.pone.0005512. Epub 2009 May 13.

15.

Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.

Helanterä I, Lautenschlager I, Koskinen P.

Nephrol Dial Transplant. 2009 Jan;24(1):316-20. doi: 10.1093/ndt/gfn558. Epub 2008 Oct 8.

16.

Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.

Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, Viklicky O.

J Am Soc Nephrol. 2012 Sep;23(9):1588-97. doi: 10.1681/ASN.2012010100. Epub 2012 Aug 23.

17.

New developments in the management of cytomegalovirus infection after solid organ transplantation.

Eid AJ, Razonable RR.

Drugs. 2010 May 28;70(8):965-81. doi: 10.2165/10898540-000000000-00000. Review.

PMID:
20481654
18.

Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.

Caldés A, Gil-Vernet S, Armendariz Y, Colom H, Pou L, Niubó J, Lladó L, Torras J, Manito N, Rufí G, Grinyó JM.

Transpl Infect Dis. 2010 Jun;12(3):204-12. doi: 10.1111/j.1399-3062.2009.00481.x. Epub 2009 Dec 9.

PMID:
20002612
19.

Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure.

Lefeuvre S, Chevalier P, Charpentier C, Zekkour R, Havard L, Benammar M, Amrein C, Boussaud V, Lillo-Le Louët A, Guillemain R, Billaud EM.

Transpl Infect Dis. 2010 Jun;12(3):213-9. doi: 10.1111/j.1399-3062.2010.00491.x. Epub 2010 Jan 20.

PMID:
20102551
20.

Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.

Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W.

Ann Intern Med. 2015 Jan 6;162(1):1-10. doi: 10.7326/M13-2729.

PMID:
25560711
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk